Klotho Neurosciences Faces Delisting Concerns

Ticker: GRMLW · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1907223

Klotho Neurosciences, INC. 8-K Filing Summary
FieldDetail
CompanyKlotho Neurosciences, INC. (GRMLW)
Form Type8-K
Filed DateOct 21, 2024
Risk Levelhigh
Pages2
Reading Time2 min
Key Dollar Amounts$1
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, corporate-actions

Related Tickers: KLTO

TL;DR

Klotho Neurosciences might get delisted - big trouble for shareholders.

AI Summary

Klotho Neurosciences, Inc. filed an 8-K on October 21, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of October 14, 2024. The company, formerly known as ANEW Medical, Inc. and Redwoods Acquisition Corp., is incorporated in Delaware and has its principal business address in New York, NY.

Why It Matters

This filing indicates potential issues with Klotho Neurosciences' ability to remain listed on its exchange, which could significantly impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading and investor confidence.

Key Players & Entities

FAQ

What specific listing rule or standard has Klotho Neurosciences failed to satisfy?

The filing does not specify the exact rule or standard that Klotho Neurosciences has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is October 14, 2024.

When was Klotho Neurosciences, Inc. previously known as?

Klotho Neurosciences, Inc. was formerly known as ANEW Medical, Inc. and prior to that, Redwoods Acquisition Corp.

What is the company's state of incorporation?

The company is incorporated in Delaware.

What is the primary business address of Klotho Neurosciences, Inc.?

The primary business address is 13576 Walnut Street, Suit.

Filing Stats: 504 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-10-21 16:56:43

Key Financial Figures

Filing Documents

01. Notice of Delisting or Failure to Satisfy a Continued

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 15, 2024, Klotho Neurosciences, Inc. (the "Company") received a delinquency notification letter (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") due to the failure of the Company's common stock to maintain a minimum bid price of $1 per share for 30 consecutive business days as required by Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until April 14, 2025, to regain compliance. To regain compliance, prior to April 14, 2025, the closing bid price of the Company's common stock must be at least $1 for a minimum of ten consecutive business days. If the Company fails to timely regain compliance with Nasdaq Listing Rules, the Company's common stock will be subject to delisting from Nasdaq. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 21, 2024 KLOTHO NEUROSCIENCES, INC. By: /s/ Joseph Sinkule Name: Joseph Sinkule Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing